


PROMEGA RECEIVES PATENT FOR APOPTOSIS MARKER ANTIBODIES

In February 2002, the U.S. Patent and Trademark Office issued a patent (U.S. Pat. No. 6,350,452) to Promega for novel apoptosis marker antibodies and their use. The antibodies specifically recognize the new amino terminus of a protein cleaved by a protease during apoptosis and thus are indicators of apoptosis. The antibody(ies) developed under this methodology are not immunoreactive with the non-cleaved protein. An integral step of apoptosis is specific cleavage within specific proteins by cellular caspases. Promega's Anti-PARP p85 Fragment pAb^(a), developed under this patent, has demonstrated its usefulness as an in situ marker of apoptosis, specifically recognizing the neo-epitope of the p85 fragment of poly(ADP-ribose) polymerase resulting from caspase cleavage of that protein. For more details on this antibody, please go to our online catalog at: www.promega.com

The development of this technology emphasizes Promega's position as a global leader in providing innovative solutions and technical support for the life sciences industry.

(a)Products may be covered by pending or issued patents. Please visit our Web site for more information.

DeadEnd is a trademark of Promega Corporation.



Anti-PARP p85 Fragment pAb and TUNEL double-labeling of apoptotic Jurkat cells. Cells were labeled with the Anti-PARP p85 Fragment pAb (Cat.# G7341; red) and the DeadEND™ Fluorometric TUNEL System^(a) (Cat.# G3250; green). The colocalization of cleaved PARP in cells containing TUNEL-positive nuclei demonstrates that the Anti-PARP p85 Fragment pAb specifically labels apoptotic cells. Protocols developed and performed at Promega.

Z794CA08_9A

BIOPHARMACEUTICAL TECHNOLOGY CENTER INSTITUTE UPCOMING COURSES

Introductory Level Courses

Introduction to Pharmaceutical Quality and Regulations

Madison Area Technical College Course
Spring 2003, dates to be determined

PCR: Methods and Applications

Madison Area Technical College Course
Fall 2002, dates to be determined

Molecular Technologies for the Clinical Laboratory

January 20–24 and May 12–16, 2003

Intermediate Level Courses

Molecular Approaches to Neuroscience: Gene Expression and Cell Analysis

June 2003

Techniques in Bioinformatics and Comparative Genomics

2003, dates to be determined

Computational Approaches to Analyzing Gene Expression Data

2003, dates to be determined

Advanced Level Courses

Current Techniques in Protein and Genetic Engineering

University of Wisconsin credit option
Tentative dates: August 6–14, 2003

For more information about course content or registration information, contact Karin Borgh, Executive Director of the BioPharmaceutical Technology Center Institute at: kborgh@promega.com

Electronic registration forms and the latest information on course dates and content can be found at: www.btc.org